Intraoperative lymphatic mapping for early-stage melanoma of the head and neck**,*

https://doi.org/10.1016/S0002-9610(97)00150-5Get rights and content

background

We previously reported dye-directed intraoperative lymphatic mapping and selective sentinel lymphadenectomy for primary cutaneous melanomas draining to the neck lymph nodes. In this study we determined whether combining the dye with a radiopharmaceutical agent would enhance our rate of sentinel node detection.

methods

One hundred seventeen patients with primary cutaneous melanomas of the upper chest and head and neck underwent preoperative cutaneous lymphoscintigraphy to confirm lymphatic drainage to neck nodes, followed by intraoperative lymphatic mapping and sentinel lymphadenectomy. In 94 cases, isosulfan blue dye was injected at the primary site; in the remaining 23 cases, a 1:3 mixture of radiopharmaceutical and dye was injected, and a hand-held probe was used to determine the radioactive counts.

results

Preoperative cutaneous lymphoscintigraphy identified 129 drainage basins; 12 patients (10%) had dual-basin drainage. During intraoperative lymphatic mapping and sentinel lymphadenectomy, 183 sentinel nodes were identified and excised from 120 basins (1.5 nodes/basin). The blue dye alone identified sentinel nodes in 93 of 101 basins (92%). The probe identified sentinel nodes in 28 of 28 basins, only one of which failed to reveal blue-staining sentinel nodes; thus, the probe plus dye identified sentinel nodes in 27 of 28 basins (96%). Histopathologic analysis revealed metastasis in sentinel nodes from 11 patients (12%) who underwent sentinel lymphadenectomy with blue dye alone and in 3 patients (13%) who underwent sentinel lymphadenectomy with dye plus probe. There were no same-basin recurrences over a mean follow-up of 46 months (range 1 to 125).

conclusions

Selective sentinel lymphadenectomy is a highly accurate method of staging the regional nodes in patients with primary tumors of the head and neck. Although we initially demonstrated the utility of this technique with blue dye alone, our results now suggest that the combination of dye and radiopharmaceutical may be a more sensitive method to detect sentinel nodes.

References (16)

  • O'BrienCJ et al.

    Prediction of potential metastatic sites in cutaneous head and neck melanoma using lymphoscintigraphy

    Am J Surg

    (1995)
  • VeronesiU et al.

    Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities

    Cancer

    (1982)
  • SimFH et al.

    A prospective randomized study of the efficacy of routine elective lymphadenectomy in man-agement of malignant melanoma

    Cancer

    (1978)
  • VeronesiU et al.

    Inefficacy of immediate node dissection in Stage I melanoma of the limbs

    NEJM

    (1977)
  • BalchCM et al.

    Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger

    Ann Surg

    (1996)
  • RobinsonDS et al.

    Regional lymphatic drainage in primary malignant melanoma of the trunk determined by colloidal gold scanning

  • MortonDL et al.

    Technical details of intraoperative lymphatic mapping for early stage melanoma

    Arch Surg

    (1992)
  • ReintgenD et al.

    The orderly progression of melanoma nodal metastases

    Ann Surg

    (1994)
There are more references available in the full text version of this article.

Cited by (133)

  • Elective management of regional nodal basins in cutaneous squamous cell carcinoma of the head and neck: Controversies and contemporary perspectives

    2021, Oral Oncology
    Citation Excerpt :

    Specifically, the superficial lymphatic system appears to be of fundamental importance, particularly external jugular nodal tissue, as well as peri-facial and peri-parotid nodes. Moreover, head and neck melanoma SLNB studies have shown high rates of discordance (24–43%) between predicted drainage patterns on the basis of primary site location and identified sentinel node, as well as drainage to multiple SLNs, often in several nodal basins, in up to 74% of patients[83–86]. Whilst ongoing SLNB studies specific to cSCCHN (discussed in subsequent section) may help to clarify this further, at present it would seem that any END should be guided by lymphoscintigraphy as a minimum.

  • Contemporary use of sentinel lymph node biopsy in the head and neck

    2016, World Journal of Otorhinolaryngology - Head and Neck Surgery
  • Hot or not? the 10% rule in sentinel lymph node biopsy for malignant melanoma revisited

    2014, Journal of Plastic, Reconstructive and Aesthetic Surgery
    Citation Excerpt :

    Some of these were found to be positive for tumour presence.3–5 A number of early studies sought to define the sentinel node in terms of absolute radiation count, in vivo or ex vivo radiation count relative to the background radioactivity, or relative to the most radioactive node in the basin.5–9 Since McMasters' paper analysing the results of the Sunbelt Melanoma Trial in 20019 the “10% rule” has been widely followed.

  • Treatment of the parotid gland in cutaneous melanoma

    2008, Operative Techniques in Otolaryngology - Head and Neck Surgery
    Citation Excerpt :

    The gamma counter will help identify the sentinel node as well as the color of the node. A node that is both blue and has a high gamma count is more likely to be the actual sentinel node.7 The gamma probe should be used to take counts of the isolated node and the rest of the specimen to ensure that there is not a second sentinel node in the specimen, as well as the surgical bed to ensure complete removal.

  • Melanocytic Lesions of the Eyelid and Ocular Adnexa

    2022, Albert and Jakobiec's Principles and Practice of Ophthalmology: Fourth Edition
View all citing articles on Scopus
**

Presented at the 43rd Annual Meeting of the Society of Head and Neck Surgeons, Cancún, Mexico, April 10–12, 1997.

*

Supported by grant CA 29605 from the National Cancer Institute and by funding from the Wrather Family Foundation (Los Angeles) and the Steele Foundation (Phoenix).

1

Dr. Essner is a recipient of an American Cancer Society Career Development Award.

View full text